Moxifloxacin is an antibiotic, used to treat bacterial infections, including pneumonia, conjunctivitis, endocarditis, tuberculosis, and sinusitis.

1. 1

2. Magferat MiLii

3. Rise out of Falling Situation…

4.  Moxifloxacin was patented in 1988 and approved
for use in the United States in 1999.
 It is approved by the U.S. Food and Drug
Administration (FDA) (December 1999) for the
treatment of certain bacterial infections.
 It is on the World Health Organization's (WHO)
List of Essential Medicines.
4
Magferat MiLii, PMD

5.  Moxifloxacin is a 4th generation synthetic broad
spectrum antibiotic, and fluoroquinolone class of
antibacterial drug.
 It has activity against a wide range of gram-positive,
gram-negative, anaerobic and atypical bacteria.
5
Magferatun Nessa MiLii, PMD

6. It acts by
inhibiting
Topoisomerase II
(DNA Gyrase) and
Topoisomerase IV
which are necessary
for bacterial
DNA replication,
transcription &
repair.
6
Magferatun Nessa MiLii, PMD

7. Acute bacterial sinusitis,
Acute exacerbation of chronic bronchitis,
Community acquired pneumonia,
Uncomplicated & complicated skin and skin
structure infections,
Complicated intra-abdominal infections
Pelvic inflammatory disease.
7
Magferatun Nessa MiLii, PMD

8. Moxifloxacin Hydrochloride 400 mg Tablet:
Acute Bacterial Sinusitis: 7-10 days.
Acute Bacterial Exacerbation of Chronic Bronchitis: 5-10 days.
Community-Acquired Pneumonia: 7-14 days.
Uncomplicated Skin and Skin Structure Infections: 7 days.
Complicated Skin and Skin Structure Infections : 7-21 days.
Complicated Intra-Abdominal Infections: 5-14 days.
Pelvic Inflammatory Disease: 14 days.
8
Magferatun Nessa MiLii, PMD

9. Common side effects include -
 Nausea.
 Vomiting.
 Stomach Pain.
 Diarrhea.
 Constipation.
 Headache
 Dizziness
 Heartburn.
9
Magferatun Nessa MiLii, PMD

10. Pregnancy & Lactation:
Pregnancy Category is not classified.
Renal or hepatic impaired patients:
No dose adjustment is necessary for patients with renal
or hepatic impairment.
Pediatric patients:
Safety and effectiveness of Moxifloxacin in paediatric
patients and adolescent less than 18 years of age have
not been established.
10
Magferatun Nessa MiLii, PMD

11. US-FDA Approved for Severe Bacterial Infection.
High rate of Clinical Success.
Rare chance of Resistance.
Once Daily Dosing.
Least time to Cure.
Safe in Renal & Hepatic Impairment.
Perfect for Switch Therapy.
11
Magferatun Nessa MiLii, PMD

12. Specialist General
Surgeons MBBS
ENT Specialists GP
Medicine Specialists & who has the
potentiality to
prescribe.
Chest Specialist
Gynecologists
Urologists
12
Magferatun Nessa MiLii, PMD

13. 13